Photo of Kevin M. Hart

As we have previously reported, thousands of lawsuits have been filed against Takeda Pharmaceutical Company for its medication Actos after studies revealed that diabetics taking the drug may be at an increased risk of developing bladder cancer. In 2011, the U.S. Food and Drug Administration (FDA) warned that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.

A plaintiff, alleging Actos caused his bladder cancer, was recently awarded $2.3 million in compensatory damages by a jury in Pennsylvania state court. The jury found that Takeda showed “reckless indifference” to the plaintiff’s health by hiding Actos’ risks and awarded another $1.3 million in punitive damages. There are approximately 8,000 other similar lawsuits currently pending in federal and state courts across the country.

If you believe you have experienced adverse side-effects from taking Actos, contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.

The litigation against manufacturers of pelvic mesh devices continues to increase nationwide. A pelvic mesh implant is a synthetic material implanted and tied to ligaments or bone to lift and support internal organs. The implants were introduced over a decade ago, and can serve as an alternative to a hysterectomy. Thousands of women, who were allegedly uninformed about the dangers involved with the mesh implants, have since complained of injuries, including severe pain, infections and bleeding that often require follow-up surgeries.

There are over 10,000 lawsuits pending against C.R. Bard for the Avaulta device. The majority of these cases are consolidated as part of a federal multidistrict litigation (MDL) before U.S. District Judge Joseph Goodwin in the Southern District of West Virginia. As we previously reported, C.R. Bard agreed to settle 500 of those cases for an undisclosed amount.

Judge Goodwin has urged C.R. Bard to seriously consider a global settlement. As Bloomberg reported, Judge Goodwin told attorneys for C.R. Bard “I can’t imagine a corporation facing potentially billions of dollars in verdicts wouldn’t find it advisable to try and achieve a settlement for a much lesser sum.” Despite this warning, the remaining C.R. Bard cases are being prepared for trial. Attorneys for C.R. Bard recently asked Judge Goodwin to delay the upcoming trial by one month, arguing that his comments regarding a settlement unfairly prejudiced the jury pool. Judge Goodwin denied the defendant’s application, finding the trials should proceed as planned.

If you or a loved one has experienced any injury from the use of a vaginal mesh implant, please contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against a manufacturer of the vaginal mesh device.

The trial of plaintiff Kathleen Herlihy-Paoli started last week in federal court in Dallas, Texas. The Paoli trial is the first of more than 6,000 cases filed across the country that have been consolidated in a Multidistrict Litigation (“MDL”) before the Honorable Edward Kinkeade, United States District Court Judge in the Northern District of Texas.

Plaintiffs allege that the Pinnacle metal-on-metal hip replacement device, manufactured by DePuy, has a higher-than-normal failure rate. Additionally, some plaintiffs have complained that the device has caused metal poisoning, called metallosis, due to high levels of chromium and/or cobalt. Plaintiffs’ lawyers have argued that the Pinnacle hips suffered from design flaws that were ignored by DePuy. As reported by Bloomberg, the federal jury was told that DePuy’s attempts to convince doctors that the metal-on-metal version of its Pinnacle hip implant was safe amounted to “marketing run amok.” The decision reached by the jury in this trial could help determine the outcome of the entire centralized litigation.

If you have had a hip replacement, which used the DePuy Pinnacle device, you can contact Stark & Stark to speak to one of the Mass Tort Attorneys, free of charge, who can help assess any claims that you might have against DePuy.

As we previously reported, an Atlantic County jury awarded a former nurse $3.35 million in compensatory damages and $7.76 million in punitive damages for injuries she suffered from a pelvic mesh implant made by Johnson & Johnson.

The Johnson & Johnson subsidiary, Ethicon, maker of the Gynecare Prolift pelvic mesh product, filed a motion requesting a new trial following the jury’s decision. The Presiding Civil Judge in Atlantic County Superior Court, Carol E. Higbee, recently denied Ethicon’s motion. Judge Higbee found that “there was strong evidence presented and multiple sources of evidence that in fact there were many problems with this product.”

More than 5,900 similar lawsuits alleging injury related to pelvic mesh devices are currently pending. If you or a loved one has experienced any injury from the use of a pelvic mesh implant, please contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Johnson & Johnson.

As we have previously reported, the makers of Plavix®, Sanofi-Aventis and Bristol-Myers Squibb, have been fined for engaging in anti-competitive behavior related to the sale and marketing of the medication. Plavix® is a blood thinner prescribed to prevent heart attacks, strokes and blood clotting. However, the users of Plavix® have alleged various forms of severe side-effects. Reportedly, these side-effects include: gastrointestinal bleeding, cerebral bleeding, bleeding ulcers, Thrombotic Thrombocytopenic Purpura (TTP), heart attack, stroke and death.

Plavix® is the second most commonly prescribed drug on the U.S. market to prevent heart attacks and stroke.  The medication, known as a “clopidogrel,” is a blood thinner that belongs to a category of drugs called antiplatelets. The drug works to prevent blood clots.

Hawaii Attorney General David Louie recently filed a lawsuit against Bristol-Myers Squibb and Sanofi-Aventis alleging unfair and deceptive marketing of the blood-thinning drug to Hawaii consumers. The suit alleges that the manufacturers of Plavix®, began deceptively and unfairly labeling and marketing the drug in 1998 by failing to disclose that Plavix® has a diminished or no effect on approximately 30 percent of the population because they metabolize the drug poorly, due to their genetic traits or because they take other drugs that affect the body’s ability to metabolize Plavix®. The drug does not prevent heart attacks, strokes, or vascular death in such patients but instead puts them at considerable risk for gastrointestinal bleeding and other complications.

If you feel you have experienced any side-effects from taking Plavix®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Plavix® manufacturers.

As we have previously reported, the American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications (Januvia/Janumet/Byetta/Victoza) to make patient level data on their products available for an independent review. Research into the safety of these incretin medications continues across the globe.

A recent study published in the medical journal, Expert Opinion on Drug Safety, confirms other U.S. studies that link incretin mimetic medications to pancreatic damage. The researchers from Ferrara, Italy, looked at 1,169 adverse drug reaction reports that concerned incretin mimetics and found 90 instances of pancreatitis and elevated pancreatic enzymes, with more than a third of those cases serious. This raises concerns that cases of chronic pancreatitis may lead to pancreatic cancer among some users.

If you or a loved one have suffered from pancreatitis or pancreatic cancer after taking Januvia/Janumet, Byetta or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any potential claims.

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant.  Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, recently signed Case Management Order 48. Judge Herndon ordered the parties to “designate up to three cases for inclusion as an early trial case” by December 16, 2013. The Court will select four cases for trial by January 23, 2014. The current trial dates for these cases are set for February 16, 2014; August 11, 2014; November 3, 2014 and January 5, 2015.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

As we have previously reported, the United States Judicial Panel on Multidistrict Litigation (JPML) granted multidistrict litigation (MDL) treatment to the incretin mimetic litigation, meaning that all federal lawsuits filed across the United States are now centralized in one judicial district. The incretin mimetic litigation, which includes the medications Byetta, Januvia/Janumet and Victoza, was centralized in the Southern District of California. This consolidation streamlines the pretrial discovery process, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.

The federal court recently held its first status conference in the MDL proceedings. The Honorable Anthony J. Battaglia, District Court Judge, scheduled the conference to discuss the appointment of lead and liaison counsel for the plaintiffs and defendants. The parties prepared a Joint Status Report that addressed various discovery and case related matters in the litigation. There are roughly 100 cases currently pending and it is expected that thousands more will follow in the near future.

If you or a loved one has suffered from pancreatitis or pancreatic cancer after taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any potential claims.

As we previously reported, the United States Judicial Panel on Multi-District Litigation (MDL) convened to determine whether the cases, known as IN RE: INCRETIN MIMETICS PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the pretrial discovery process, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.

The Judicial Panel granted MDL status and signed a Transfer Order on August 26, 2013. The cases will be consolidated and transferred to U.S. District Court in the Southern District of California and presided over by the Honorable Anthony J. Battaglia. The Judicial Panel decided the Southern District of California was appropriate given the volume of filings that currently pend in that district and the fact that Judge Battaglia is familiar with the case.  Notably, the case caption has been changed to “In re Incretin-Based Therapies Products Liability Litigation.”

If you or a loved one has suffered from pancreatitis or pancreatic cancer after taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any potential claims.